Johnson & Johnson stock extends its gains as Q2 earnings and guidance support a higher valuation

Johnson & Johnson stock (ISIN US4781601046) is trading above $260 in mid-August 2026, supported by steady earnings growth in the latest quarter and continued confidence reflected in the company’s full-year 2026 guidance.

Market data as of August 13, 2026 show the shares closing at $262.12 on the New York Stock Exchange, up 0.48% on the day, with a market capitalization of $631.24 billion based on that price level.

For investors, the combination of high-quality earnings, an ongoing dividend, and a premium valuation profile is central to how Johnson & Johnson stock is being positioned in diversified portfolios.

Q2 2026 earnings growth and guidance

Recent coverage of Johnson & Johnson’s financial results indicates that the company last reported quarterly earnings on July 15, 2026, delivering earnings per share of $2.90 for the quarter, ahead of the consensus estimate of $2.84.

In the same Q2 2026 update, Johnson & Johnson reported revenue of $25.31 billion, slightly above the $25.06 billion that analysts had expected, and up 6.6% compared with the same quarter of the previous year.

The company’s net margin in that Q2 2026 period stood at 21.48%, while return on equity was 32.42%, underscoring a business model that is able to convert a large global revenue base into robust profitability.

The EPS growth also shows a clear year-over-year improvement: in the prior-year quarter Johnson & Johnson earned $2.77 per share, meaning Q2 2026 EPS rose by $0.13, or about 4.7%, compared with the same period a year earlier.

Alongside the quarterly figures, Johnson & Johnson has set its fiscal 2026 guidance for earnings per share in a range between $11.60 and $11.75, signaling that management expects the profit momentum seen in the latest quarter to extend across the year.

For portfolio managers, that guidance range helps frame valuation and risk, since it anchors expectations for full-year earnings against which the current share price and multiple can be assessed.

Valuation and market performance

On the valuation side, recent market-data overviews show Johnson & Johnson trading at a trailing twelve-month price-to-earnings ratio of 30.00 based on current earnings and the share price as of August 13, 2026.

With the shares at $262.12 and the company’s trailing twelve-month earnings per share at 8.74, the implied P/E multiple corroborates that investors are assigning a premium valuation to the stock compared with many large-cap healthcare peers.

One quantitative comparison tool that looks at intrinsic value and quality scores currently assigns Johnson & Johnson a fair value estimate of $169 per share, versus the actual market price around $262, indicating an overvaluation of 36% relative to that fair value benchmark.

By contrast, that same comparison shows another large-cap pharma name trading at $1,209 against a fair value of $389, or 68% above its calculated fair value, suggesting Johnson & Johnson is still the less overvalued of the two while earning a higher quality score of 81 out of 100.

Recent consensus data from analyst compilations point to an average rating of Moderate Buy on Johnson & Johnson stock and a consensus price target of $268.22, only modestly above the current trading level.

Another compiled analyst view lists an overall recommendation of Buy with a price target of $269.18, reinforcing the picture that Wall Street expects incremental upside rather than a dramatic re-rating from current levels.

From a performance perspective, one recent analysis notes that Johnson & Johnson’s share price stood at $261.31 on August 13, 2026, up 49.82% over the past year, versus a 20.56% gain for the S&P 500 index, meaning the stock has delivered more than double the benchmark’s return over that period.

That same review highlights Johnson & Johnson’s beta of 0.23, indicating that historically the stock has moved much less than the broader market, yet over the past twelve months it has produced outsized returns despite its defensive profile.

Dividend and income profile

Johnson & Johnson continues to underpin its investment case with a regular dividend distribution, reflecting its long-standing status as an income-oriented blue-chip in the healthcare sector.

Recent filings and dividend declarations show a quarterly dividend of $1.34 per share to shareholders of record on August 25, with payment scheduled for September 8, 2026.

On an annualized basis that dividend level corresponds to $5.36 per share, which at a share price around $262 translates into a dividend yield of roughly 2.0% for investors holding Johnson & Johnson stock.

Because the yield is derived from both a sizable cash payout and a strong share price, it positions the company as a blend of income and growth within equity portfolios focused on healthcare and defensive sectors.

Over time, Johnson & Johnson’s pattern of consistent dividend payments and increases has been a central part of its appeal to long-term investors seeking a combination of capital preservation and modest appreciation.

Quality metrics and peer comparison

Beyond headline earnings and dividends, Johnson & Johnson’s qualitative and quantitative scores provide further insight into how the market currently perceives the company’s fundamental strength.

In the latest fair value and quality comparison featuring Johnson & Johnson and another major pharmaceutical group, Johnson & Johnson receives a quality score of 81 out of 100, higher than its peer’s score of 69 out of 100.

The same comparison emphasizes that Johnson & Johnson’s overvaluation relative to estimated fair value is less extreme than that of its peer, aligning with the market view that strong balance sheet metrics and diversified operations warrant a somewhat elevated valuation.

Investors often weigh this type of fair value gap against forward earnings guidance and risk factors, using the combination of quality scores and valuation metrics to inform decisions on position sizing rather than binary buy-or-sell calls.

In practical terms, the data suggest that while Johnson & Johnson stock may not be a deep-value opportunity at current levels, it offers a comparatively attractive risk-adjusted profile among large-cap healthcare names with similar global reach.

Representative product: pharmaceuticals and medical devices

Johnson & Johnson operates through several major segments, including pharmaceuticals, medical devices, and consumer health products, providing a diversified revenue base across different areas of healthcare demand.

In pharmaceuticals, the company markets a wide range of therapies spanning oncology, immunology, neuroscience, infectious diseases, and cardiovascular medicine, each contributing to recurring revenue streams anchored in long-term treatment regimens.

Its medical devices segment includes products for surgery, orthopedics, and cardiovascular interventions, where technology innovation and clinical outcomes play a central role in winning and maintaining hospital and physician customers.

Consumer health brands, spanning categories such as over-the-counter pain relief, allergy treatments, and personal care, round out the portfolio, supporting brand recognition and cash flow even when prescription or device cycles fluctuate.

For investors evaluating Johnson & Johnson stock, this multi-segment structure means that no single product defines the company’s outlook, and that resilience often comes from the ability to offset weakness in one area with strength in another.

Closing view on Johnson & Johnson stock

As of August 13, 2026, Johnson & Johnson shares closed at $262.12 on the New York Stock Exchange in regular trading, implying a market capitalization of $631.24 billion at that level.

The stock’s strong one-year performance, premium valuation metrics, and solid Q2 2026 earnings and guidance together frame a picture of a defensive healthcare name that has recently delivered growth-like returns, a combination that continues to influence how investors allocate capital to Johnson & Johnson within diversified portfolios.

Fact box

Company: Johnson & Johnson

ISIN: US4781601046

Ticker: JNJ

Exchange: NYSE

Price (as of August 13, 2026, 4:00 p.m. ET): $262.12 USD

Market cap: $631.24 billion (as of August 13, 2026)

Sector / Industry: Health care / Pharmaceuticals and medical devices

Index membership: Dow Jones Industrial Average and S&P 500